1-8 of 8
Daniela Hernandez
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Is There a Disparity in Oncological Outcomes for Hispanics? Analysis of Burkitt Lymphoma

Carolina Velez-Mejia, MD, Daniela Hernandez, MD, Joel E Michalek, PhD, Qianqian Liu, PhD, Adolfo Enrique Diaz Duque, MDMSc
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-136485
Published: 2020
Journal Articles

A First Large Statewide Population Based Study Evaluating Racial Differences in Treatment and Survival between Hispanics and Non-Hispanics with Diffuse Large B Cell Lymphoma (DLBCL)

Daniela Hernandez, MD, Carolina Velez-Mejia, MD, Joel E Michalek, PhD, Qianqian Liu, PhD, Adolfo Enrique Diaz Duque, MDMSc
Journal: Blood
Blood (2020) 136 (Supplement 1): 9.
https://doi.org/10.1182/blood-2020-142151
Published: 2020
Journal Articles

Diffuse Large B Cell Lymphoma (DLBCL) Experience in a Majority-Minority Community: The UT Health San Antonio Story

Daniela Hernandez, MD, Michelle Janania Martinez, MD, Juan F Garza, MD, Tyler W Snedden, MD, Adolfo E Diaz, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2916.
https://doi.org/10.1182/blood-2019-127485
Published: 2019
Journal Articles

A Phase (ph) 1b/2 Study of TAK-659, an Investigational Dual FLT-3 and SYK Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML)

Keith Pratz, MD, Mark J. Levis, MD, John C Morris, MD, Trisha Wise-Draper, MD PhD, Moshe Levy, MD, Dale L. Bixby, Patrick Burke, MD, Daniela Hernandez, MD, Kate Stumpo, BA, Karuppiah Kannan, Emily Sheldon-Waniga, PhD, Shining Wang, MD, Steven Zhang, PhD, Yaping Shou, MD PhD, Jessica K. Altman, MD, Jason Kaplan, MD, Olga Frankfurt, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2622.
https://doi.org/10.1182/blood.V130.Suppl_1.2622.2622
Published: 2017
Journal Articles

Bone Marrow Stroma Protects FLT3 Acute Myeloid Leukemia (AML) through CYP3A4-Mediated Drug Metabolization of FLT3 Tyrosine Kinase Inhibitors (TKIs)

Yu-Ting Chang, MS, Daniela Hernandez, MD, Gabriel Ghiaur, MD PhD, Mark J. Levis, MD, Richard J. Jones, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2519.
https://doi.org/10.1182/blood.V130.Suppl_1.2519.2519
Published: 2017
Journal Articles

Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor

Lauren Y. Lee, Daniela Hernandez, Trivikram Rajkhowa, Samuel C. Smith, Jayant Ranganathan Raman, Bao Nguyen, Donald Small, Mark Levis
Journal: Blood
Blood (2017) 129 (2): 257–260.
https://doi.org/10.1182/blood-2016-10-745133
Published: 2017
Includes: Supplemental data
Journal Articles

A Phase I Study of the Multi-Targeted Tyrosine Kinase Inhibitor Cabozantinib in Patients with Acute Myeloid Leukemia

Amir T. Fathi, MD, Traci M. Blonquist, MS, Mark J. Levis, MD PhD, Daniela Hernandez, MD, Karen K. Ballen, MD, David E. Avigan, MD, Robin Joyce, MD, Malgorzata McMasters, MD, Emma Logan, Gabriela S. Hobbs, MD, Andrew M. Brunner, MD, Christine Connolly, Ashley M. Perry, BS, Christelle Joseph, Tina T. Som, Aura Y. Ramos, Donna S. Neuberg, ScD, Philip C. Amrein, MD
Journal: Blood
Blood (2016) 128 (22): 5218.
https://doi.org/10.1182/blood.V128.22.5218.5218
Published: 2016
Journal Articles

RAR-Alpha Targeting Compounds Overcome Bone Marrow (BM) Stromal Protection of AML By CYP26

Kelly J Norsworthy, MD, Daniela Hernandez, MD, Meng Su, BS, Megan E McCray, BA, Christopher A Esteb, BS, Roshantha A Chandraratna, PhD, B. Douglas Smith, MD, Richard J Jones, MD, Gabriel Ghiaur, MD PhD
Journal: Blood
Blood (2015) 126 (23): 2474.
https://doi.org/10.1182/blood.V126.23.2474.2474
Published: 2015